Bibliography
- Furtado GH, Nicolau DP. Overview perspective of bacterial resistance. Expert Opin Ther Pat 2010;20:1273-6
- Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008;29:552-9
- Supuran CT. Bacterial carbonic anhydrases as drug targets: towards novel antibiotics ? Front Pharmacol 2011;2:34
- Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81
- Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767-77
- Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199-229
- Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165-80
- Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
- Nishimori I, Minakuchi T, Vullo D, Carbonic anhydrase inhibitors. cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009;52:3116-20
- Burghout P, Vullo D, Scozzafava A, Inhibition of the beta-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: towards innovative drug design of antiinfectives ? Bioorg Med Chem 2011;19:243-8
- Winum JY, Kohler S, Supuran CT. Brucella carbonic anhydrases: new targets for designing anti-infective agents. Curr Pharm Des 2010;16:3310-16
- Vullo D, Nishimori I, Minakuchi T, Inhibition studies with anions and small molecules of two novel beta-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett 2011;21:3591-5
- Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622-30
- Nishimori I, Minakuchi T, Kohsaki T, Carbonic anhydrase inhibitors. The beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007;17:3585-94
- Minakuchi T, Nishimori I, Vullo D, Molecular cloning, characterization and inhibition studies of the Rv1284 beta-−carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009;52:2226-32
- Guzel O, Maresca A, Scozzafava A, Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem 2009;52:4063-7
- Carta F, Maresca A, Suarez Covarrubias A, Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009;19:6649-54
- Nishimori I, Minakuchi T, Maresca A, The beta-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des 2010;16:3300-9
- Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2012; In press
- Maresca A, Scozzafava A, Vullo D, Supuran CT. Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2012; [Epub ahead of print]
- Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012;11:25-36
- Sharma PC, Jain A, Jain S, Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzyme Inhib Med Chem 2010;25:577-89
- Narasimhan B, Sharma D, Kumar P, Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones. J Enzyme Inhib Med Chem 2011;26:720-7
- Maresca A, Temperini C, Vu H, Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057-62
- Patel MN, Parmar PA, Gandhi DS. Third generation fluoroquinolones antibacterial drug based mixed-ligand Cu(II) complexes: structure, antibacterial activity, superoxide dismutase activity and DNA-interaction approach. J Enzyme Inhib Med Chem 2011;26:188-97
- Patel MN, Parmar PA, Gandhi DS. Synthesis, characterization and DNA binding and cleavage properties of ruthenium(II) complexes with various polypyridyls. J Enzyme Inhib Med Chem 2011;26:734-41
- Astrazeneca AB- Astrazeneca UK Ltd. Heterocyclic urea derivatives and methods of use thereof. WO2010142978; 2010